Tau is an axonal protein known to form abnormal aggregates and is the biomarker of Alzheimer's disease. Metal-based therapeutics for inhibition of Tau aggregation is limited and rarely reported in the contemporary science. Here, the first example is reported of a rationally designed molecular cobalt(II)-complexes for effective inhibition of Tau and disaggregation of preformed Tau fibrils. The mechanistic studies revealed that the prevention of Tau aggregation by CBMCs is concentration-dependent and Tau seldom exhibits conformational changes. Interestingly, CBMCs play a dual role by causing disassembly of preformed aggregates as well as complete Tau inhibition. We believe that this unprecedented finding by the newly developed molecular complexes has a potential to lead to developing innovative metal-based therapeutics for Alzheimer's disease.
INTRODUCTION
adjacent to hexapeptide motif in the second and third repeat of Tau. The effect of copper on Tau protein aggregation via. oxidation of cysteine residues was the key interest for copper binding. 23 In AD brain, Tau hyperphosphorylates and aggregates to form PHFs, ions such as aluminium(III) specifically interact with its phosphorylated epitopes. 24 These findings suggest that phosphorylated Tau is triggered for aggregation in the presence of aluminium(III).
Further, the effect of aluminium maltolate administration was reported for neurodegeneration in rabbits. 25 However, the effect of zinc(II) on Tau fibrillization in physiological conditions is contradicting to that of copper(II) and aluminium(III). The lower levels or deficiency of zinc(II) would enhance Tau aggregation by decreasing the expression of Tau or by reducing the ability of Tau to interact with MTs. Sequestration of zinc(II) by extracellular senile plaques leads to decreased intracellular zinc levels, which ultimately leads to NFTs formation. Importantly, the presence of higher intracellular zinc levels leads to hyperphosphorylation of Tau at S214, which eventually forms aggregates. 26 Furthermore, ferric iron can lead to Tau aggregation in vitro, and its reduced form causes hyperphosphorylation of Tau. 27, 28 Other targets of AD such as acetylcholine esterase and monoamine oxidase are also altered by the levels of metal ions. 29 Notably, other neurodegenerative diseases like Creutzfeldt Jakob disease are also known to be caused by the presence of unbalanced metal ions. The cellular prion protein PrP c undergoes conformational changes to PrP Sc and leads to prion disease. Similarly, the pathological conformational changes in the prion protein were observed upon its interaction with copper(II). 30 The significance of copper interaction with octarepeats in PrP was revealed by using NMR, tryptophan fluorescence emission and Raman spectroscopy.
30,31
In our present studies, we screened the effect of rationally designed molecular cobalt based metal complexes (CBMCs; Fig. 1B ) on Tau aggregation and found that these complexes are effective in preventing the formation of a toxic population of Tau. The CBMCs were effective in inhibiting polymerization of Tau in concentrationdependent manner. The efficacy of these metal complexes were analysed by fluorescence assay, studying the conformational change in Tau by spectroscopic techniques and the morphology of aggregates was observed by microscopic analysis.
RESULTS AND DISCUSSION

CBMCs, as a barrier for Tau aggregation
Tau protein is one of the major microtubule-associated proteins in neuronal axons that mainly functions to stabilize and assemble MTs. 32 Tau is a soluble protein and adopts natively unfolded structure in solution. 33 The repeat domains of Tau and the flanking proline-rich regions confers the property of MT binding and assembly (Fig. 1A) .
The repeat domains of Tau represents the core of PHFs. 34 The hexapeptide motifs in repeat 2 and 3 form the basic motif for aggregation. In vitro conditions, heparin is used as an inducer to enhance Tau aggregation. 34 Heparin binds to the positively charged residues of flanking repeats 2 and 3, and thus leading to charge neutralization. Further, the binding of heparin also leads to change in conformation of β-sheet, which serves as a nucleation centre for the aggregation. Tau protein was diluted in assembly buffer, incubated for the formation of aggregates in presence or absence of CBMCs and the extent of aggregates formation was monitored by ThS. Our interest in metal-based therapeutics in AD began with the discovery of novel Co(II) complexes, since cobalt is relatively abundant, and biorelevant. The reaction of the tridentate ligand with CoCl 2 in methanol at 65 °C for 4 hours results the corresponding cobalt-pincer complexes in excellent yields (See ESI, S1-S7). All the complexes were wellcharacterized and the structure of NNN-L2 CoCl 2 was confirmed by a single-crystal X-ray diffraction study (Fig.   1C ).
The Co(II)-complexes (CBMCs) were incubated with constant Tau concentration of 0.91 mg mL -1 , with increasing concentrations of metal complexes (0.01, 0.025, 0.05 and 0.1 mg mL -1 ). The aggregation of full-length Tau with
CBMCs at the higher concentration substantially decreased the ThS fluorescence ( Fig. 2A , B and C), which indicates the prevention of aggregates formation. Further, we have quantified inhibition, which revealed that L2 is more potent with 92.5% inhibition at the lowest concentrations of 0.025 mg mL -1 , whereas, L3 and L1 showed 85.5 and 73.9% inhibition, respectively. At the highest concentration of 0.1 mg mL -1 , they showed up to 93% inhibition (Fig. 2D) . The higher order species formed upon Tau aggregation were observed by SDS-PAGE analysis (Fig. 2E, F and G). In presence of metal complexes, Tau was able to form higher order aggregates which completely faded away over the time. At 0 hour the intensity of Tau was high which decreased with increasing complex concentration (Fig. 2H ). This data is in agreement with the size-exclusion chromatography analysis which is evidenced by the retention volume that metal complexes prevent the aggregation of Tau to higher molecular weight species in vitro (Fig. S12A , B, C and D).
Native conformation of Tau maintained by CBMCs
The changes in Tau conformation due to metal complexes were studied by CD spectroscopy. Tau has no secondary structure and exists as a random coil protein, which absorbs around 190 nm. The aggregated Tau shows a shift towards the higher wavelength, which signifies the transition of the random coil to β-sheet conformation. In the presence of CBMCs, the typical random coil conformation of full-length (Fig. 3A , B and C) was not altered. These results signify the effect of these complexes in preventing aggregates formation. Tau protein in vitro forms fibrillar morphology in the presence of heparin, which is observed as a long filamentous structure. The extent of aggregate formation by Tau in presence of L1, L2 and L3 were studied by Transmission electron microscopy (TEM), which discloses the vigour of the CBMCs in completely preventing the aggregates formation ( Fig. 3D , E, F and G).
Further, the EDAX (Energy Dispersive X-Ray) revealed that the negligible amount of CBMCs was associated with Tau, which denotes that Tau was devoid of conjugation with CBMCs (data not shown). X-ray photon electron spectroscopy analysis showed that the oxidation state of the CBMCs remains unchanged during Tau aggregation (data not shown). The formation of higher order species by full-length Tau at 0 hour in presence of CBMCs stimulated us to study its role on soluble Tau. However, surprisingly no higher order aggregates were observed upon incubation at 37 °C ( Fig. S9A ) and this manifests the inability of the complexes to form toxic Tau species when compared with the control (Fig. S9B) . The initial Tau conformation plays a critical role in order to form the nucleus, which further accelerates the formation of aggregates. Here, we show that these molecular Co(II)-complexes did not induce the conformational changes in soluble Tau and maintained its native conformation (Fig.   S10A , B and C). To support the data, we further studied the effect of CBMCs on soluble full-length Tau (Fig.   S11A , B and C) for their aggregation. Tau aggregates were not observed, which indicated that the Co(II)-complexes did not lead to the formation of aggregates during initial stages of Tau assembly.
Destabilization of preformed Tau fibrils
We further investigated the role of CBMCs on disassembly of Tau PHFs. This would enhance both properties of aggregation inhibition and disaggregation of Tau. The preformed Tau aggregates were incubated with various concentrations of L1, L2 and L3 and it was observed that L3 was more effective in disaggregating Tau when compared to L1 and L2 (Fig. 4A, B and C) . At a concentration of 0.5 mg mL -1 , L3 showed about 77.4% of inhibition, but L1 and L2 showed 73.5% and 71.9% inhibition, respectively (Fig. 4D) . Furthermore, SDS-PAGE analysis showed a decrease in the aggregates by CBMCs in time dependent manner (Fig. 4E, F (Fig. S8A) . However, at the end of 120
hours, there was a definite decrease in the formation of PHFs (Fig. 6A , B, C and D). Overall, these results suggest the efficacy of CBMCs in preventing the formation of Tau aggregates that could be toxic and hence, it can be a potent therapeutic agent to AD.
In recent years, several drugs failed in the clinical trials which emphasize the urge to develop and screen different natural as well as synthetic molecules to target AD pathology. Although AD has multifaceted effectors like kinases, proteases, oxidative stress etc., the structure of the protein plays very important role in interaction and further change in its conformation can lead to either oligomers or aggregates formation. It has been suggested that the oligomeric precursors to amyloid fibrils may substantially be more toxic than the fibers themselves. Even if this was the case, amyloid fibrils are likely to play an important role, either as reservoirs or sinks to toxic oligomers. Hence, a detailed screening of compounds could help in discovering potential drugs that prevent protein aggregation in AD.
The role of metal ions in association with proteins and leading to their aggregation is a well-known phenomenon. 43 Copper is also known for reactive oxygen species (ROS) production in presence of Amyloid β which leads to cytotoxicity. 44 45 Copper interacts with Amyloid β and leads to a reduction in the content of β-sheet conformation that would further form amorphous aggregates. 46 In our current studies, CBMCs did not drive conformational changes in full-length Tau. The soluble Tau has also manifested the signature of typical random-coil conformation in presence of metal complexes, which indicates that CBMCs does not drive conformational changes in Tau. Tau usually accumulates to form filamentous aggregates, but aluminium leads to the formation of amorphous aggregates. 47 In complement to the CD spectroscopy of soluble Tau, TEM analysis also suggests the absence of toxic Tau species. The interaction and affinity of the prion protein for copper and silver is dependent on their conformation of the protein. 48 The SEC analysis clearly indicated that the higher order species of Tau aggregates was prevented by CBMCs ( Fig. S12 ).
Direct interaction of CBMCs with Tau
Isothermal titration calorimetry (ITC) is the direct method to obtain free energy (ΔG), enthalpy (ΔH) and entropy kcal/mol, respectively.
Cobalt inhibits the human Tau aggregation mediated cytotoxicity:
Metals are an essential components of the brain at physiological levels but, their accumulation at higher concentration would be detrimental. Metals are known to exert toxicity in either of the following ways, by inhibiting PP2A or activating kinases such as cdk5/p25, GSK3β etc. The neurons isolated from hippocampus were treated with iron, this led to oxidative stress which ultimately caused Tau hyperphosphorylation via., cdk5/p25 complex. 50 Similarly, studies in the rat primary cortical neurons showed that zinc caused phosphorylation of Tau at Ser262, which was marked as an early pathological events in AD. 51 Here, the toxicity of these compounds were analysed by treating the SH-SY5Y cells with CBMCs in presence of Tau aggregates (Fig. 6E ). The neuronal SH-SY5Y cells treated with Tau aggregates showed 59% cell toxicity at the concentration of 5 µM. However, this toxicity was arrested in the presence of CBMCs treatment. Interestingly, CBMCs displayed a dose-dependent inhibition of the cytotoxic effect induced by full-length Tau aggregates (Fig. 6F) . Further, at CBMCs concentration of 100 µg/mL the cell viability was almost restored to 80%. These observations drive towards the conclusion that CBMCs are non-toxic to cells and moreover they reduce the toxicity of Tau aggregates, thus maintaining the cell viability.
Further, at CBMCs concentration of 100 µg/mL the cell viability was almost restored to 80%. These observations drive towards the conclusion that CBMCs are non-toxic to cells and moreover they reduce the toxicity of Tau aggregates, thus maintaining the cell viability.
In summary, a newly developed molecular Co(II)-complexes (CBMCs) showed significant role in inhibition and disaggregation of Tau. The cytotoxicity studies on human neuroblastoma SH-SY5Y cells revealed that the present CBMCs are non-toxic in nature under in vitro conditions. We firmly believe that the present molecular cobalt(II)-complexes can be a potential therapeutic agent for Alzheimer's Disease and related neurodegenerative diseases.
METHODS
Materials or Chemicals:
MES, heparin, BES, BSA, BCA and ThS were purchased from Sigma. IPTG and DTT were purchased from Calbiochem. Other chemicals such as ampicillin, NaCl, EGTA etc. were purchased from MP.
Cell culture related chemicals and plastics were purchased by Sigma and Thermo scientific Pvt Ltd.
Experiments were carried out using standard Schlenk techniques. All solvents were reagent grade or better. Deuterated solvents were used as received. Acetonitrile was refluxed over P 2 O 5 and freshly distilled under argon atmosphere. Metal complexes (CoCl 2 ) and other chemicals used in the reactions were used without additional purification. Thin layer chromatography (TLC) was performed using silica gel pre-coated glass plates, which were visualized with UV light at 254 nm or under iodine. eV. High-resolution mass spectra (HRMS) were obtained on a High-resolution mass spectra (HRMS) were obtained by fast atom bombardment (FAB) using a double focusing magnetic sector mass spectrometer and electron impact (EI) ionization technique (magnetic sector-electric sector double focusing mass analyzer). 
2, 6-Bis(piperazin-1-yl-methyl)pyridine (NNN-L2):
Step-1: synthesis of boc NNN: solution of 2, 6-bis(bromomethyl)pyridine (1 g, 3.77mmol) in acetonitrile (40 mL) was added drop wise to solution of 1-boc-peprazine (1.4037 g, 7.54 mmol) and K 2 CO 3 (1.56 g, 1.13 mmol) in CH 3 CN (20 mL), the resulting reaction mixture was allowed to stir for 14 hours at 85°C after cooled to room temperature, the reaction mixture was extracted in chloroform. The organic fraction were combined and dried over an- 
Step-2: synthesis of NNN-L2: boc NNN (0.8g) was dissolved MeOH (15 mL) and followed by added 1N HCl (8 mL), then the mixture was allowed to stir for 6hrs at 60 o C. After cooling the reaction mixture to room temperature, it was neutralized with aqueous solution of 5% NaHCO 3 , then the solvent was evaporated in vacuum. The resulting sticky product was further dissolved in ethanol and filtered. The filtrate was concentrated in vacuum, afforded yellow oil product. Yield (0.75 g, 75% 
Chart 1. NNN-pincer type cobalt complexes
Synthesis of (NNN-
L1)CoCl 2 : Cobalt chloride hexahydrate (0.312 g, 1.34 mmol) in methanol (15 mL) was added drop wise to solution of NNN-L1 (0.408 g, 1.34 mmol) in MeOH (15 mL) with stirring. The resulting reaction mix
Expression and Purification of Tau:
The recombinant full-length and four repeat Tau were expressed in BL21 * strain of E.coli. Cells were induced with 0.5 mM IPTG after the OD at A 600 reached to 0.5 to 0.6. The cells were allowed to grow at 37°C post-induction and were harvested by pelleting at 4000 rpm, at 4°C for 10 minutes. The pellet obtained was resuspended in 50 mM MES buffer pH 6.8 containing 1 mM EGTA, 2 mM MgCl 2 , 5 mM DTT, 1 mM PMSF, protease inhibitor cocktail and was lysed by using constant cell disruption system. The purification was done as described previously with minor changes. 52 The concentrated protein was aliquoted, snap freezed and stored in -80°C until further used. The concentration was estimated using bichinchoninic acid (BCA) method.
Preparation of Tau aggregates:
Tau was induced to aggregates formation as described previously with minor modifications. 52 In presence of heparin (17,500 Da) at the ratio of 4:1,Tau was polymerized in assembly buffer containing 20 mM BES, pH 7.4, 25 mM NaCl, 1 mM DTT, 0.01% NaN 3 and protease inhibitor cocktails. The reaction mixture was incubated at 37°C and the aggregates formation was monitored by ThS fluorescence, 53,54 SDS-PAGE and TEM at certain time intervals. Tau protein was allowed to assemble in presence and absence of compounds in increasing concentrations with constant Tau concentrations of 0.91 mg mL -1 . The changes in the conformation of Tau protein was monitored by CD spectroscopy.
Disaggregation assay:
The potency of the metal complexes for disaggregating the preformed Tau aggregates was analyzed. Soluble Tau 
SDS-PAGE analysis for Tau aggregates:
The effect of the compounds on inhibiting the aggregates formation by Tau was observed by SDS-PAGE. 55, 56 The reaction mixture incubated with and without compound were collected at different time intervals of 0 hour, 24 hour and 72 hours (end point) and resolved 10% SDS-PAGE using miniVE Vertical Electrophoresis System from GE healthcare. Further the SDS-PAGE were quantified and analyzed using Gel Doc™ XR+ System and image lab software.
Soluble Tau Assay:
The soluble Tau was studied in presence of metal complexes alone to analyze the conformational changes occurring due to the compound. 0.91 mg mL -1 was incubated for 1 hour at 37°C with and without different concentrations of 0.01 mg mL -1 , 0.025 mg mL -1 , 0.05 mg mL -1 and 0.1 mg mL -1 of metal complexes. At the end of one hour the samples were analyzed by SDS-PAGE, TEM and CD spectroscopy to monitor the formation of aggregates and change in Tau conformation, respectively.
CD spectroscopy:
The conformational changes in Tau was analyzed by CD spectroscopy in the far UV region. Tau is a random coiled protein and upon aggregation it acquires β-sheet conformation. The impact of the compounds on preventing the formation of β-sheet structure was studied by CD spectroscopy. The spectra was collected as described previously, in Jasco J-815 spectrometer, by using cuvette with 1 mm path length. 57 The measurements were performed in the range of 250 nm to 190 nm, with a data pitch of 1.0 nm, scanning speed of 100 nm/min. All the spectra were obtained at 25°C. The reaction mixture was diluted to 0.13 mg mL -1 in 50 mM phosphate buffer, pH 6.8. The effect of compound on soluble Tau was also studied by incubating Tau along with compounds alone at 37°C and the spectra was read at 25°C.
Transmission Electron Microscopy (TEM):
The extent of aggregates formed in presence of the metal complexes was analyzed by TEM (Tecnai T-20). The assay mixture was diluted to 0.04 mg mL -1 final concentration, spotted on the carbon coated copper grid of 400 mesh and incubated for 45 seconds. The excess Tau aggregates were removed by incubating the grid in water for 30 seconds and this was repeated twice. The grid was further stained by 2% uranyl acetate for 1 minute to observe the morphology of aggregates under TEM.
Size-exclusion chromatography (SEC):
The HMW species formed by Tau polymerization was analyzed by SEC. [58] [59] [60] Tau protein was diluted to a concentration of 4.58 mg mL -1 in assembly buffer along with heparin in a ratio of 4:1 and incubated at 37°C in presence and absence of 0.1 mg mL -1 of NNN-L2CoCl 2 . Tau was subjected to SEC using superdex 75 PG in order to resolve aggregated Tau from the soluble, which was accessed as decrease in retention volume at different time points of 0, 2 and 24 hours in presence and absence of NNN-L2CoCl 2 .
Isothermal titration calorimetry:
Isothermal titration calorimetry (ITC) was carried out to understand the thermodynamics behind Tau interaction with CBMCs. Here, the titration was done using 2.3 mg/mL of full-length Tau 
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The synthetic rationally designed molecular cobalt complexes (CBMCs) prevents the polymerization of Tau protein, as well as destabilizes the pre-formed fibrils. Thus, CBMCs are identified as a hit compound with significance to prevent AD as evidenced by various biochemical and biophysical analysis.
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